Skip to main content

Advertisement

SpringerLink
Log in

The new face of nucleolin in human melanoma

  • Original article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Nucleolin is multifunctional protein mainly present in nucleoli but also detected in cytoplasm and plasma membranes. Extranuclear nucleolin differs from the nuclear form by its glycosylation. Studies on expression of nucleolin in breast cancer suggest a possible association to the metastatic cascade. In the present study, Vicia villosa lectin (VVL) precipitation followed by subsequent polyacrylamide gel electrophoresis and mass spectrometry analysis demonstrates nucleolin as a VVL-positive glycoprotein expressed in melanoma. The presence of VVL-positive nucleolin in the melanoma cell membrane and cytoplasm was confirmed by confocal microscopy. Using bioinformatic peptide prediction programs, nucleolin was shown to contain multiple possible MHC class-I binding peptides in its sequence which makes nucleolin an interesting melanoma marker and target for immunodiagnostic and possibly therapeutic purposes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Aldi S, Della Giovampaola C, Focarelli R, Armini A, Ziche M, Finetti F, Rosati F (2009) A fucose-containing O-glycoepitope on bovine and human nucleolin. Glycobiology 19:337–343

    Article  PubMed  CAS  Google Scholar 

  2. Bubenik J (2005) MHC class I down-regulation, tumour escape from immune surveillance and design of therapeutic strategies. Folia Biol (Praha) 51:1–2

    CAS  Google Scholar 

  3. Carpentier M, Morelle W, Coddeville B, Pons A, Masson M, Mazurie J, Legrand D (2005) Nucleolin undergoes partial N- and O-glycosylations in the extracellular cell compartment. Biochemistry 44:5804–5815

    Article  PubMed  CAS  Google Scholar 

  4. Chen C, Chiang S, Yeh N (1991) Increased stability of nucleolin in proliferating cells by inhibition of its self-cleaving activity. J Biol Chem 266:7754–7758

    PubMed  CAS  Google Scholar 

  5. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E (2003) Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 163:871–878

    Article  PubMed  CAS  Google Scholar 

  6. Dall’Olio F (1996) Protein glycosylation in cancer biology: an overview. Clin Mol Pathol 49:126–135

    Article  Google Scholar 

  7. Deng J-S, Ballou B, Hofmeister JK (1996) Internalization of anti-nucleolin antibody into viable HEp-2 cells. Mol Biol Rep 23:191–195

    Article  PubMed  CAS  Google Scholar 

  8. Fonsatti E, Di Giacomo AM, Maio M (2004) Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy? J Trans Med 2:21

    Article  Google Scholar 

  9. Ginisty H, Sicard H, Roger B, Bouvet P (1999) Structure and function of nucleolin. J Cell Sci 112:761–772

    PubMed  CAS  Google Scholar 

  10. Glithero A, Tormo J, Haurum JS, Arsequell G, Valencia G, Edwards J, Springer S, Townsend A, Pao YL, Wormald M, Dwek RA, Jones EY, Elliott T (1999) Crystal structures of two H-2Db/glycopeptides complexes suggest a molecular basis for CTL cross-reactivity. Immunity 10:63–74

    Article  PubMed  CAS  Google Scholar 

  11. Hakomori S (2002) Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 99:10231–10233

    Article  PubMed  CAS  Google Scholar 

  12. Harms G, Kraft R, Grelle G, Volz B, Dernedde J, Tauber R (2001) Identification of nucleolin as a new L-selectin ligand. Biochem J 360:531–538

    Article  PubMed  CAS  Google Scholar 

  13. Haurum JS, Arsequell G, Lellouch AC, Wong SY, Dwek RA, McMichael AJ, Elliott T (1994) Recognition of carbohydrate by major histocompatibility comlex class I-restricted, glycopeptides-specific cytotoxic T lymphocytes. J Exp Med 180:739–744

    Article  PubMed  CAS  Google Scholar 

  14. Haurum JS, Tan L, Arsequell G, Frodsham P, Lellouch AC, Moss PA, Dwek RA, McMichael AJ, Elliott T (1995) Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition. Eur J Immunol 25:3270–3276

    Article  PubMed  CAS  Google Scholar 

  15. Haurum JS, Hoier IB, Arsequell G, Neisig A, Valencia G, Zeuthen J, Neefjes J, Elliott T (1999) Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med 190:145–150

    Article  PubMed  CAS  Google Scholar 

  16. Hoja-Łukowicz D, Lityńska A, Pocheć E, Przybyło M, Kremser E, Ciołczyk-Wierzbicka D, Laidler P (2006) Identification of PNA-positive proteins in the primary uveal melanoma cell line by mass spectrometry. Acta Biol Cracov Ser Zool 48:39–47

    Google Scholar 

  17. Hovanessian AG, Puvion-Dutilleul F, Nisole S, Svab J, Perret E, Deng JS, Krust B (2000) The cell-surface-expressed nucleolin is associated with the actin cytoskeleton. Exp Cell Res 261:312–328

    Article  PubMed  CAS  Google Scholar 

  18. Huang Y, Shi H, Zhou H, Song X, Yuan S, Luo Y (2006) The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 107:3564–3571

    Article  PubMed  CAS  Google Scholar 

  19. Joo EJ, ten Dam GB, van Kuppevelt TH, Toida T, Linhardt RJ, Kim YS (2005) Nucleolin: acharan sulfate-binding protein on the surface of cancer cells. Glycobiology 15:1–9

    Article  PubMed  CAS  Google Scholar 

  20. Kanitakis J, Al-Rifai I, Faure M, Claudy A (1998) Differential expression of cancer associated antigen T (Thomsen-Friedenrich) and Tn to the skin in primary and metastatic carcinomas. J Clin Pathol 51:588–592

    Article  PubMed  CAS  Google Scholar 

  21. Kastrup IB, Stevanovic S, Arsequell G, Valencia G, Zeuthen J, Rammensee HG, Elliot T, Haurum JS (2000) Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo. Tissue Antigens 56:129–135

    Article  PubMed  CAS  Google Scholar 

  22. Laidler P, Lityńska A, Hoja-Łukowicz D, Łabędź M, Przybyło M, Ciołczyk-Wierzbicka D, Pocheć E, Trębacz E, Kremser E (2006) Characterization of glycosylation and adherent properties of melanoma cell lines. Cancer Immunol Immunother 55:112–118

    Article  PubMed  CAS  Google Scholar 

  23. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685

    Article  PubMed  CAS  Google Scholar 

  24. Lau SK, Dennis JW (2008) N-glycans in cancer progression. Glycobiology 18:750–760

    Article  PubMed  CAS  Google Scholar 

  25. Legrand D, Vigie K, Said EA, Elass E, Masson M, Slomiany MC, Carpentier M, Briand JP, Mazurier J, Hovanessian AG (2004) Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur J Biochem 271:303–317

    Article  PubMed  CAS  Google Scholar 

  26. Lisowska E (2002) The role of glycosylation in protein antigenic properties. CMLS, Cell Mol Life Sci 59:445–455

    Article  CAS  Google Scholar 

  27. Monzavi-Karbassi B, Luo P, Jousheghany F, Torres-Quinones M, Cunto-Amesty G, Artaud C, Kieber-Emmos T (2004) A mimic of tumor rejection antigen-associated carbohydrates mediates an antitumor cellular response. Cancer Res 64:2162–2166

    Article  PubMed  CAS  Google Scholar 

  28. Renkvist N, Castelli C, Robbins PF, Parmanini G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3–15

    Article  PubMed  CAS  Google Scholar 

  29. Said EA, Courty J, Svab J, Delbe J, Krust B, Hovanessian AG (2005) Pleiotrophin inhibits HIV infection by binding the cell surface-expressed nucleolin. FASEB J 272:4646–4659

    CAS  Google Scholar 

  30. Salazar R, Brandt R, Kellermann J, Krantz S (2000) Purification and characterization of a 200 kDa fructosyllysine-specific binding protein from cell membranes of U937 cells. Glycoconjugate J 17:713–716

    Article  CAS  Google Scholar 

  31. Singhal A, Fohn M, Hakomori S (1991) Induction of α-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular response for active immunotherapy in mice. Cancer Res 51:1406–1411

    PubMed  CAS  Google Scholar 

  32. Speir JA, Abde-Motal UM, Jondal M, Wilson IA (1999) Crystal structure of an MHC class I presented glycopeptides that generates carbohydrate-specific CTL. Immunity 10:51–61

    Article  PubMed  CAS  Google Scholar 

  33. Springer GF (1989) Tn epitope (N-acetyl-D-galactosamineα-O-serine/threonine) density in primary breast carcinoma: a functional predictor of aggressiveness. Mol Immunol 26:1–5

    Article  PubMed  CAS  Google Scholar 

  34. Srivastava M, Pollard HB (1999) Molecular dissection of nucleolin’s role in growth and cell proliferation: new insights. FASEB J 13:1911–1922

    PubMed  CAS  Google Scholar 

  35. Thies A, Moll I, Berger J, Schumacher U (2001) Lectin binding to cutaneous malignant melanoma: HPA is associated with metastasis formation. Br J Cancer 84:819–823

    Article  PubMed  CAS  Google Scholar 

  36. Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373:1033–1040

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported by grants from: The European Network for the Identification and Validation of Antigens and Biomarkers in Cancer and their Application in Clinical Tumour Immunology (ENACT, 6FP of EU, LSHC-CT-2004-503306) and the Institute of Zoology, Jagiellonian University (K/ZDS/000782).

Author information

Authors and Affiliations

  1. Institute of Zoology, Jagiellonian University, Ingardena 6, 30 060, Kraków, Poland

    Dorota Hoja-Łukowicz, Małgorzata Przybyło, Ewa Pocheć, Marcelina Kremser & Anna Lityńska

  2. Institute of Medical Biochemistry, Medical College, Jagiellonian University, Kopernika 7, 31 034, Kraków, Poland

    Anna Drabik & Piotr Laidler

  3. Neurobiochemistry Department, Faculty of Chemistry, Jagiellonian University, Ingardena 3, 30 060, Kraków, Poland

    Anna Drabik & Jerzy Silberring

  4. Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstr. 55, 45122, Essen, Germany

    Dirk Schadendorf

Authors
  1. Dorota Hoja-Łukowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Małgorzata Przybyło
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ewa Pocheć
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Drabik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jerzy Silberring
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marcelina Kremser
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dirk Schadendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Piotr Laidler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Anna Lityńska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dorota Hoja-Łukowicz.

Additional information

This paper is an original contribution from the meeting which took place on 28–and 29 May, 2008, in Nottingham, UK, celebrating the contribution of Professor I.A. “Tony” Dodi (+29.1.2008) to the EU project “Network for the identification and validation of antigens and biomarkers in cancer and their application in clinical tumour immunology (ENACT)”.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoja-Łukowicz, D., Przybyło, M., Pocheć, E. et al. The new face of nucleolin in human melanoma. Cancer Immunol Immunother 58, 1471–1480 (2009). https://doi.org/10.1007/s00262-009-0705-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-009-0705-8

Keywords

Search

Navigation